Did Teleflex beat or miss consensus estimates last quarter?

What guidance did Teleflex's management provide for the next earnings period?

What factors drove the changes in Teleflex's revenue and profit?

What does Teleflex do and what are its main business segments?

What were the key takeaways from Teleflex's earnings call?

What is Teleflex's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Teleflex year over year?

What were the key takeaways from Teleflex’s earnings call?

- **NewCo Sale Priority**: Focused on selling NewCo with advanced buyer interest, targeting accretive valuation.
- **Q3 Revenue Growth**: 16.8% YoY adjusted revenue ($892.9M), driven by Vascular Intervention (+34.4% EMEA) and Surgical (+8.8%).
- **Balloon Pump Risk**: Reduced 2025 guidance by $30M due to U.S. order decline, but catheters maintain growth.
- **Tariff Mitigation**: Improved to $25-26M annual impact (-$0.50 EPS) from $29M.
- **Japan Expansion**: Barrigel launched in Japan for prostate cancer, with first cases in August.

**【Management Opening Remarks】**
- Announced the separation into RemainCo and NewCo, prioritizing the sale of NewCo due to strong buyer interest.
- Updated Italian payback measure reduced reserve by $23.7 million, with $20.1 million revenue adjustment for prior periods.

**【CEO Commentary】**
- Q3 GAAP revenue: $913 million (+19.4% YoY); adjusted revenue: $892.9 million (+16.8% YoY).
- Americas: $555.9 million (+7.5% YoY), driven by Vascular Intervention and Surgical businesses.
- EMEA: $214.1 million (+34.4% YoY), including Vascular Intervention acquisition.
- Asia: $122.9 million (+25.3% YoY), with $9 million China stocking order.
- Vascular Intervention revenue: $99 million (6.9% YoY growth), ahead of guidance.
- Intra-aortic balloon pump revenue reduced by $30 million due to U.S. order decline.
- Launched Barrigel in Japan for prostate cancer treatment.

**【CFO Financial Commentary】**
- Adjusted EPS: $3.67 (+5.2% YoY).
- Gross margin: 57.3% (-350bps YoY) due to tariffs and FX.
- Operating margin: 23.3% (-400bps YoY) from acquisition costs.
- 2025 guidance: Adjusted revenue growth 8-8.5%, EPS $14-14.20.
- Tariff impact reduced to $25-26 million ($0.50 EPS) from $29 million.

**【Q&A Highlights】**
- China stocking order expected to sell through by end-2025.
- NewCo sale prioritized over spin-off; late-stage due diligence with multiple buyers.
- Restructuring to reduce costs and relocate manufacturing by end-2028.
- Intra-aortic balloon pumps face slower U.S. conversions, but catheters remain growth driver.
- Vascular Intervention integration progressing well with no leadership turnover.

Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript

- **Revenue Beat & Growth**: Q2 revenue $780.9M (+4.2% YoY), EPS $3.73 (+9.1%). 2025 guidance raised to 7.7-8.7% constant currency growth, EPS $13.90-14.30.
- **BIOTRONIK Acquisition**: €704M deal adds $204M 2025 H2 revenue, targeting 6%+ 2026+ growth. Cath lab access and product synergies expected.
- **Tariff Mitigation Success**: 2025 impact reduced to $29M ($0.55/share) vs. prior $55M, driven by USMCA compliance and pricing.
- **Strategic Separation**: NewCo sale process advanced with multiple buyer expressions; spin by mid-2026 if sale fails.
- **Urology Rebound Potential**: CMS 2026 rule proposes 10% UroLift uplift, 40% Barrigel increase in office, supporting 2026 recovery.

**【CEO Summary Section】**
- **Q2 Revenue Performance**: $780.9 million (+4.2% YoY GAAP, +1% constant currency). Exceeded high end of guidance ($769-777M). Adjusted EPS of $3.73 (+9.1% YoY).
- **Geographic Growth**: Americas (+2%), EMEA (-2.1%), Asia (+1.2%). China sequential improvement expected to continue.
- **Product Highlights**: 
  - Vascular Access (+1.4%): PICCs double-digit growth, EZ-IO strong.
  - Interventional (+19.3%): Balloon pumps, OnControl, complex catheters drive growth.
  - Surgical (+1.4%): North America mid-single-digit growth offset by China procurement.
- **Strategic Updates**: 
  - Completed acquisition of BIOTRONIK Vascular Intervention business for €704M. 2025 H2 contribution: €177M ($204M). 2026+ growth target: 6%+.
  - Progressing separation of Teleflex and potential sale of NewCo. Multiple buyer expressions of interest.
  - CMS 2026 proposed rule positive for UroLift and Barrigel reimbursement.

**【CFO Financial Commentary】**
- **Margins**: Adjusted gross margin 59.7% (-110bps YoY), operating margin 26.9% (+20bps YoY). Tariffs impact reduced to $29M ($0.55/share) vs. prior $55M ($1.05/share).
- **2025 Guidance Update**: 
  - Constant currency growth: 7.7-8.7% (prev 1-2%). GAAP growth: 9-10% ($3.32-3.52B).
  - Adjusted EPS: $13.90-14.30 (up $0.70, driven by lower tariffs and operational performance).
  - Gross margin: 58.75-59.5% (prev 58.25-59.25%).
- **Acquisition Impact**: €177M ($204M) contribution in H2. Slight 2025 EPS dilution offset by operational efficiency.

**【Q&A Key Highlights】**
- **BIOTRONIK Integration**: 50% EMEA, 25% Americas, 25% APAC revenue. Synergies via cath lab access and product portfolio combination (e.g., complex catheters + drug-eluting stents).
- **Tariff Mitigation**: 50% reduction in 2025 impact. Strategies include USMCA compliance, pricing, and supply chain optimization.
- **Urology Outlook**: CMS rule proposed 10% UroLift uplift in office/ASC. Barrigel 40% office, 9% ASC/hospital increase. 2026 recovery potential.
- **NewCo Sale Progress**: Preliminary buyer meetings, due diligence underway. Mid-2026 spin if sale not completed.
- **Interventional Growth**: High single to low double-digit 2025 growth. Balloon pumps double-digit Q2, moderating in Q4 due to tougher comp.


Teleflex (TFX)-31 Jul 25-2025 Q2 Earnings call transcript

- **Q1 2025 Results**: Revenue $700.7M (-5% YoY GAAP), EPS $2.91 (-9.3% YoY). Key headwinds: EMEA order softness, China procurement, OEM contract impacts.
- **Strategic Moves**: 
  - Exploring NewCo sale/spin to unlock value; $1.1B BIOTRONIK acquisition on track for Q3 close.
  - QuikClot Control+ expanded indication adds $150M+ U.S. market opportunity.
- **Tariff Impact**: $55M annualized headwind, partially mitigated by USMCA compliance and pricing (30-50bps acceleration).
- **Growth Drivers**: Vascular Access (PICC double-digit growth), Interventional (balloon pumps strong in Americas), and BIOTRONIK integration targeting $80M+ market.
- **China Recovery**: Sequential improvement expected; Q1 softness due to procurement and comps.


**【CEO Summary Section】**
- Q1 2025 revenue: $700.7M (-5% YoY GAAP, -3.8% adjusted constant currency). Adjusted EPS: $2.91 (-9.3% YoY). Key drivers: softness in EMEA orders (recovered in April), China volume-based procurement, and OEM contract impacts.
- **Geographic Performance**: 
  - Americas: $475.7M (-3.2% YoY), impacted by OEM decline and UroLift office sites of service challenges.
  - EMEA: $151.2M (-2.8% YoY), strong Surgical and Vascular Access offset by anesthesia weakness.
  - Asia: $73.8M (-9.7% YoY), China headwinds expected to improve sequentially.
- **Product Line Highlights**: 
  - Vascular Access: $182.4M (+1.9% YoY), PICC double-digit growth, EZ-IO solid performance.
  - Interventional: $137.5M (+3.2% YoY), intra-aortic balloon pumps strong in Americas.
  - Anesthesia: $86.6M (-8.6% YoY), offset by Endotracheal Tubes and hemostatic product growth.
- **Strategic Updates**: 
  - Proposed separation into RemainCo and NewCo to enhance value; exploring parallel spin/sale of NewCo.
  - $1.1B acquisition of BIOTRONIK Vascular Intervention business on track for Q3 2025 close, targeting $80M+ coronary perforation market.
  - QuikClot Control+ expanded indication adds $150M+ addressable market in U.S.

**【CFO Financial Commentary】**
- **Margins**: 
  - Adjusted gross margin: 60.4% (-70bps YoY) due to macro cost pressures and product mix.
  - Operating margin: 24.7% (-190bps YoY) driven by gross margin decline and investments.
- **Cash Flow**: Q1 2025 cash flow from operations: $73.3M (-39.5% YoY) due to working capital changes.
- **Balance Sheet**: Cash: $317.5M, net leverage: 1.8x.
- **2025 Guidance Adjustments**: 
  - Revenue growth: 1-2% (adjusted constant currency), GAAP range updated to $3.086B-$3.117B.
  - Tariff impact: $55M (recorded in COGS), 50% from China, 35% from Mexico (25% rate).
  - Adjusted EPS: $13.20-$13.60 (vs. prior $13.95-$14.35), reflecting $1.05 tariff headwind partially offset by $0.30 benefits.
  - Gross margin: 58.25-59.0% (down 200bps YoY, 180bps from tariffs).

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: 
  - $55M impact assumes current tariffs; exploring USMCA compliance, supply chain optimization, and price increases.
  - 50% of inventory now USMCA-compliant; targeting 30-50bps pricing acceleration in 2025.
- **NewCo Interest**: Significant inbound interest from strategics and PE; parallel spin/sale process aims to maximize shareholder value.
- **BIOTRONIK Synergies**: Combining Teleflex's complex catheter portfolio with BIOTRONIK's drug-coated balloons and resorbable scaffolds to target $80M+ coronary perforation market.
- **China Recovery**: Sequential improvement expected in China business; Q1 softness due to volume-based procurement and tough comps.
- **OEM Outlook**: Order rates improved in Q1; expect sequential growth with $7M Q1/Q2 contract impact, anniversaried in Q3.


Teleflex (TFX)-1 May 25-2025 Q1 Earnings call transcript

- **Q4 2024 Strong Performance**: Revenue $795M (+2.8% YoY), EPS $3.89 (+15%). Interventional (+18.7%) and Surgical (+12.3%) lead growth.
- **2025 Guidance**: 1-2% adj. const. curr. growth, EPS $13.95-$14.35. $300M share buyback to enhance returns.
- **Strategic Moves**: $760M BIOTRONIK acquisition for >6% 2026+ growth. Spin-off into RemainCo (6%+ growth) and NewCo (low-single-digit growth).
- **Key Risks**: UroLift softness in 2025, OEM inventory management, Mexico tariff exposure.


**【CEO & CFO Financial Summary】**
- **Q4 2024 Revenue**: $795.4M (+2.8% YoY GAAP, +3.2% adj. const. curr.).
- **Adjusted EPS**: $3.89 (+15.1% YoY). Interventional (+18.7%), Surgical (+12.3%) drove growth. Palette Life Sciences exceeded $75M guidance.
- **2024 Full Year**: Adj. const. curr. revenue +3.1%, EPS $14.01. Gross margin +120bps to 60.1%, operating margin +60bps to 27.6%.
- **Cash Flow**: $638.3M (+24.7% YoY). Noncash goodwill impairment charge $240M (Interventional Urology NA). Net leverage 1.5x.

**【2025 Guidance】**
- **Revenue Growth**: 1-2% adj. const. curr. (ex $13.8M Italy impact). EPS $13.95-$14.35. Gross margin 60.25-61%, operating margin 26.6-27%.
- **Share Repurchase**: $300M accelerated program, $500M total authorized. Interest expense ~$75M, tax rate ~13.5%.

**【Strategic Acquisitions & Spin-Off】**
- **BIOTRONIK Vascular Intervention**: $760M (EUR) acquisition. 2025 Q4 expected close. 2026+ growth >6%, accretive $0.10 EPS first year. Portfolio includes drug-coated balloons, stents, Freesolve R&D.
- **Company Spin-Off**: Separation into RemainCo (Vascular, Interventional, Surgical) and NewCo (Urology, Acute Care, OEM). RemainCo 2026+ growth 6%+, mid-60s gross margin. NewCo low-single-digit growth, mid-50s gross margin. Tax-free distribution mid-2026.

**【Q&A Highlights】**
- **Freesolve Potential**: European pivotal trial 2027, U.S. trial TBD. Metallic scaffold advantages over polymer.
- **Sales Force Synergies**: Teleflex Americas + BIOTRONIK EMEA expansion. Shared access to cath lab procedures.
- **Tariff Risks**: Mexico manufacturing exposure. $0.10 EPS accretion from acquisition, 10%+ ROIC by year 4.
- **UroLift Recovery**: 2025 last year of U.S. reimbursement cuts. UroLift 3 dev to drive recovery.


TFX

TFX fundamentals

Earnings Call

You can ask Aime